

9-06-07

2019

dba

2019 SterlingRx, Inc.

Prescription Referral Form (I to R) NPI: 1225548480 • Ph: 888.618.4126 • F: 866.588.0371

Note: Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy. Prescribers are reminded patients may choose any pharmacy of their choice

Date Medication Needed: Ship to: Patient's Home Prescriber's Office Pharmacy to Coordinate Patient Information Please fax FRONT and BACK copy of ALL Insurance cards (Prescription and Medical). Patient Name: Birthdate: Male Female Height: Weight: Sex: Allergies: _ Patient Primary Language: English Spanish Other: Hearing Impaired _____ Secondary Phone: ______ Patient Email: _ Patient Phone Caregiver Name: ___ City: ___ ___ State: ____ Zip: _ Patient Address: _ **Provider/Prescriber Information** Clinic Name: Provider Name: __ _ DEA#: __ Provider Address: _ __ City: ___ Key Contact: Phone: Email: Fax: **Diagnosis/Clinical Information** Please FAX Clinical Notes, Labs & Tests with the prescription to expedite Prior Authorization. Other: Diagnosis/ICD-10: Diagnosis Date: **Prior Failed Treatments:** Indicate Drug Name and Length _ ALT: _____ AST: ____ of Treatment: TB Test: Positive Negative Date: _ _ LFT: _ Date: Biologicals Methotrexate Assessment-Moderate Moderate to Severe Severe Oral Meds % BSA Affected Hands Scalp Feet Groin Nails **Topicals** Patient also taking Methotrexate? Yes Nο **Injection Training:** UVA Serious or active infection present? Pharmacist to Provide Yes Nο UVB Patient Trained in MD Office Hep B ruled out or treatment started? Yes No Manufacturer Nurse Support Others Does patient have latex allergy? Yes No If Prior Authorization is Denied: Sterling will inform provider of preferred formulary alternatives and/or draft an appeal letter as advisable. Prescription Information Please be sure to choose both induction and maintenance dose where applicable. Patient Name: Patient Birthdate: Medication Dose/Strength Direction Qty. Refills Induction: Inject 100mg SC at week 0 1 0 Other-100mg/ml Solution in a Single-Dose **ILUMYA®** Prefilled Syringe Maintenance: Inject 100mg SC at week 4 and every 12 weeks thereafter 1 125mg/ml ClickJect™ Autoinjector Inject 125mg SC once a week 4 **ORENCIA®** 125mg/ml Prefilled Syringe Other: Prescriber provided patient with Otezla® 2-week Starter Pack Sample
Date Provided: _ 0 0 Starter Pack: Take one tablet by mouth in the morning on day 1, then take one tablet in 55 Starter Pack (Tritration) the morning and one tablet in the evening as directed on the starter pack **OTEZLA®** Maintenance: Take one 30mg tablet by mouth twice daily 60 30mg Tablets Other: Bridge: Take one 30mg tablet by mouth: Twice daily (x14 days, 28 tablets, 12 refills) Bridge Rx-30mg of Otezla® (commercial patients only) Once daily (x28 days, 28 tablets, 6 refills) Other: Induction Dose: Infuse 5mg/kg intravenously over approximately 2 hours at 0, 2, and 6 weeks 0 Other: _ **REMICADE®** 100mg Vial (5mg/kg) Maintenance Dose: Infuse 5mg/kg intravenously over approximately 2 hours every 8 weeks Prescriber Signature: Prescriber, please sign and date below (NO stamps please): Dispense as written: Date: Substitution Permissible: Date: I authorize Sterling Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance Prior Authorization process, nursing services, and patient assistance programs.

of Prescriptions:

IMPORTANT NOTICE: This fax is intended to be delivered to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately. Pursuant to VA/OH/MO/VT law, only 1 medication is permitted per order form. Please use a new form for additional items.